Second primary cancers in patients with castration resistant prostate cancer (BOCARP)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/26612
• EU PAS number:
  EUPAS12665
• Study ID:
  26612
• Official title and acronym:
  Second primary cancers in patients with castration resistant prostate cancer (BOCARP)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated with radium-223-dichloride.
• Study status:
  Finalised

Research institution and networks

Institutions

Leibniz Institute for Prevention Research and Epidemiology - BIPS

Germany

Contact details

Riedel Oliver

Study contact

[e-mail]

Riedel Oliver

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 10/07/2015

Actual: 10/07/2015

Data collection

Planned: 15/03/2016

Actual: 15/03/2016

Date of final study report

Planned: 30/11/2017

Actual: 20/10/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Study protocol

Initial protocol

Study 18044_Protocol_2016-03-03_final

Updated protocol

18044_study protocol_v1.2_2017-05-02

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable